Granted Patent
B2
US 12,415,795 · App. 18/189,943 · Granted Sep 16, 2025
4-(3-cyanophenyl)-6-pyridinylpyrimidine mGlu5 modulators
Inventors:
John Andrew Christopher (Cambridge, GB); Miles Stuart Congreve (Melbourn Royston, GB); Sarah Joanne Aves (Cambridge, GB); Benjamin Gerald Tehan (Cambridge, GB)
Assignee:
Nxera Pharma UK Limited
View Patent ↗
Loading inventors, assignments & file history…
Abstract
The disclosures herein relate to novel compounds of formula wherein R 1 , R 2 , R 3 and R 4 and n are defined herein, and their use in treating, preventing, ameliorating, controlling or reducing the risk of inflammation, neurological or psychiatric disorders associated with modulating mGlu5 receptor function.
Claims (19)
1. A compound of formula 3
or a pharmaceutically acceptable salt thereof, wherein
R 1 is halogen, optionally substituted C 1 -C 3 alkyl, cyclopropyl, optionally substituted C 1 -C 3 alkoxy, cyano, hydroxyl, nitro or NH 2 ;
R 2 is H or F;
R 3 is cyano;
R 4 is H, halogen, optionally substituted C 1 -C 3 alkyl, optionally substituted C 1 -C 3 alkoxy or cyano; and
n is 0-3.
2. The compound according to claim 1 , or a pharmaceutically acceptable salt thereof, wherein n is 0 or 1.
3. The compound according to claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 1 is F, Cl, OMe, CH 2 OMe, Me, fluoromethyl or cyano.
4. The compound according to claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 1 is F, Cl or cyano.
5. The compound according to claim 1 which is a compound of formula 4
or a pharmaceutically acceptable salt thereof.
6. The compound according to claim 5 , or a pharmaceutically acceptable salt thereof, wherein R 1 is F, Cl, OMe, CH 2 OMe, Me, fluoromethyl or cyano.
7. The compound according to claim 5 , or a pharmaceutically acceptable salt thereof, wherein R 1 is F, Cl or cyano.
8. A compound which is:
6-[6-(3-chloro-5-cyanophenyl)pyrimidin-4-yl]pyridine-3-carbonitrile,
or a pharmaceutically acceptable salt thereof.
9. A pharmaceutical composition comprising the compound according to claim 1 , or a pharmaceutically acceptable salt thereof.
10. A pharmaceutical composition comprising the compound according to claim 8 , or a pharmaceutically acceptable salt thereof.
Assignments (2)
CHANGE OF NAME
Recorded Aug 8, 2024
From: HEPTARES THERAPEUTICS LIMITED
To: NXERA PHARMA UK LIMITED
Reel/Frame 068230/0394 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Aug 2, 2023
From: CHRISTOPHER, JOHN ANDREW; CONGREVE, MILES STUART; AVES, SARAH JOANNE; TEHAN, BENJAMIN GERALD
To: HEPTARES THERAPEUTICS LIMITED
Reel/Frame 064472/0744 →
Priority Claims (1)
GB 1312800
· Jul 17, 2013
· national
Continuity (7)
References Cited (169)
US 7348353B2
· Gasparini et al.
· 2008
[cited by applicant]
US 7569592B2
· Cosford et al.
· 2009
[cited by applicant]
US 8084487B2
· Kuesters et al.
· 2011
[cited by applicant]
US 8536229B2
· Gasparini et al.
· 2013
[cited by applicant]
US 8703809B2
· Gomez-Mancilla et al.
· 2014
[cited by applicant]
US 9676715B2
· Denis et al.
· 2017
[cited by applicant]
US 9676745B2
· Christopher
· 2017
[cited by examiner]
US 20030195139A1
· Corsi et al.
· 2003
[cited by applicant]
US 20120039999A1
· Chatterji et al.
· 2012
[cited by applicant]
US 20160128979A1
· Thoma et al.
· 2016
[cited by applicant]
US 20230270720A1
· Dolmetsch et al.
· 2023
[cited by applicant]
AU 2014291807B2
· 2018
[cited by applicant]
CA 3181961A1
· 2022
[cited by applicant]
CN 1592743A
· 2005
[cited by applicant]
CN 1906187A
· 2007
[cited by applicant]
JP 2005516920A
· 2005
[cited by applicant]
JP 2007514790A
· 2007
[cited by applicant]
JP 2007523183A
· 2007
[cited by applicant]
JP 2011529969A
· 2011
[cited by applicant]
WO WO03051315A2
· 2003
[cited by applicant]
WO WO2003047581A1
· 2003
[cited by applicant]
WO WO2004084824A2
· 2004
[cited by applicant]
WO WO2005066155A1
· 2005
[cited by applicant]
WO WO2005080397A2
· 2005
[cited by applicant]
WO WO2009011850A2
· 2009
[cited by applicant]
WO WO2010017179A1
· 2010
[cited by applicant]
WO WO2010018154A1
· 2010
[cited by applicant]
WO WO2011091153A1
· 2011
[cited by applicant]
WO WO2012003912A1
· 2012
[cited by applicant]
WO WO2014199316A1
· 2014
[cited by applicant]
WO WO2015008073A1
· 2015
[cited by applicant]
WO WO2015197079A1
· 2015
[cited by applicant]
WO WO2019025931A1
· 2019
[cited by applicant]
WO WO2019025932A1
· 2019
[cited by applicant]
WO WO2020157640A1
· 2020
[cited by applicant]
WO WO2022013809A2
· 2022
[cited by applicant]
WO WO2022123482A1
· 2022
[cited by applicant]
WO WO2023249789A1
· 2023
[cited by applicant]
Aronica, E. et al. (2001). “Immunohistochemical localization of group I and II metabotropic glutamate receptors in control and amyotrophic lateral sclerosis human spinal cord: upregulation in reactive astrocytes,” Neuro…
[cited by applicant]
Awad, H. et al. (2000). “Activation of metabotropic glutamate receptor 5 has direct excitatory effects and potentiates NMDA receptor currents in neurons of the subthalamic nucleus,” J. of Neuroscience 20:7871-7879.
[cited by applicant]
Backstrom, Pia et al., “mGluR5 Antagonist MPEP Reduces Ethanol-Seeking and Relapse Behavior,” Neuropsychopharmacology, May 2004, vol. 29, No. 5, pp. 921-928.
[cited by applicant]
Bennet, K. et al., “Understanding exposure-receptor occupancy relationships for metabotropic glutamate receptor 5 negative allosteric modulators across a range of preclinical and clinical studies,” The Journal of Pharma…
[cited by applicant]
Blednov, Y.A. et al. (2008). “Metabotropic glutamate receptor 5 (mGluR5) regulation of ethanol sedation, dependence and consumption: relationship to acamprosate actions,” Int. Journal of Neuropsychopharmacology 11:775-7…
[cited by applicant]
Brown, Robyn M. et al., “The mGlu5 receptor antagonist MTEP attenuates opiate self-administration and cue-induced opiate-seeking behaviour in mice,” Drug and Alcohol Dependence, 2012, vol. 123, pp. 264-268.
[cited by applicant]
Bruno, V. et al. (2000). “Selective blockade of metabotropic glutamate receptor subtype 5 is neuroprotective” Neuropharmacology 39:2223-2230.
[cited by applicant]
Bundegaard, H., Design of Prodrugs, 1985, pp. 1-92, Elesevier, New York-Oxford.
[cited by applicant]
Cannady, R. et al., “Enhanced AMPA receptor activity increases operant alcohol self-administration and cue-induced reinstatement,” Addiction Biology, 2013, pp. 18:54-18:65.
[cited by applicant]
Caprioli, Daniele et al., “Effect of novel allosteric modulators of metabotropic glutamate receptors on drug self-administration and relapse: a review of preclinical studies and their clinical implications,” Biol Psychi…
[cited by applicant]
Center for Substance Abuse Treatment, “Substance Abuse: Clinical Issues in Intensive Outpatient Treatment,” Treatment Improvement Protocol (TIP) Series, 2006, No. 47. Appendix B: Urine Collection and Testing Procedures …
[cited by applicant]
Chaki, S. et al. (2013). mGiu2i3 and mGlu5 receptors: potential targets for novel antidepressants/ Neuropharmacology 66:40-52.
[cited by applicant]
Chapman, A.G. et al. (2000). “Anticonvulsant activity of two metabotropic glutamate group I antagonists selective for the mGlu5 receptor: 2-methyl-6-(phenylethynyl)-pyridine (MPEP). and (E)-6-methyl-2-styryl-pyi-idine (…
[cited by applicant]
Choi, K.Y. et al. (2011). “Expression of the metabotropic glutamate receptor 5 (mGluR5) induces melanoma in transgenic mice,” PNAS 108:15219-15224.
[cited by applicant]
Christopher, John A. et al., “Fragment and Structure-Based Drug Discovery for a Class C GPCR: Discovery of the mGlu5 Negative Allosteric Modulator HTL14242 (3-Chloro-5-[6-(5-fluoropyridin-2-yl)pyrimidin-4-yl]benzonitril…
[cited by applicant]
ClinicalTrials.gov, “Phase 1, Healthy Subject, Safety, Tolerability and Pharmacokinetic Study of mGlu5 NAM HTL0014242,” Heptares Therapeutics Limited, Mar. 11, 2021, NCT03785054 version 5, URL:https://clinicaltrials.gov…
[cited by applicant]
Cone, E. J. et al., “Interpretation of Oral Fluid Tests for Drugs of Abuse,” Annals of the New York Academy of Sciences, 2007, vol. 1098, No. 1, pp. 51-103.
[cited by applicant]
Crock, L.W. et al. (2012). “Central amygdala metabotropic glutamate receptor 5 in the modulation o visceral pain,” J. of Neuroscience 32:14217-14226).
[cited by applicant]
Doria, J.G. et al. (2013). “Metabotropic glutamate receptor 5 positive allosteric modulators are neuroprotective in a mouse model of Huntington's disease,” British Journal of Pharmacology 169:909-921.
[cited by applicant]
Elia, J. et al. (2010). “Rare structural variants found in attention-deficit hyperactivity disorder are preferentially associated with neuro developmental genes,” Molecular Psychiatry 15:637-646.
[cited by applicant]
Gasparini, F. et al. (2002). “[(3)H]-M-MPEP, a potent, subtype-selective radioligand for the metabotropic glutamate receptor subtype 5,” Bioorg. Med Chem. Lett. 12:407-409.
[cited by applicant]
Gass, J.T, et al. (2009). Positive Allosteric Modulation of mGluR5 Receptors Facilitates Extinction of a Cocaine Contextual Memory, Biol. Psychiatry 65:717-720.
[cited by applicant]
Gould, R. W. et al., “Negative allosteric modulators of the metabotropic glutamate receptor subtype 5 for the treatment of cocaine use disorder,” The Neuroscience of Cocaine, 2017, Academic Press, pp. 699-709.
[cited by applicant]
Grueter, B.A. et al. (2008). “In vivo metabotropic glutamate receptor 5 (mGluR5) antagonism prevents cocaine-induced disruption of postsynaptically maintained mGluR5-dependent long-term depression,” J. of Neuroscience 2…
[cited by applicant]
Gryczynski, J. et al., “Hair drug testing results and self-reported drug use among primary care patients with moderate-risk illicit drug use,” Drug Alcohol Depend., Aug. 1, 2014, vol. 141, pp. 44-50.
[cited by applicant]
Guglielmo, R. et al., “Pharmacological treatments in alcohol use disorders: state of art and new perspectives,” La Clinica terapeutica, 2015, vol. 166, No. 6, pp. 262-270.
[cited by applicant]
Harrisson, P. et al. (2009). “Microwave-accelerated iridium-catalyzed borylation of aromatic C—H bonds,” Org. Lett. 11:3586-3589.
[cited by applicant]
Hughes, Z.A. et al. (2012). “Negative allosteric modulation of metabotropic glutamate receptor 5 results in broad spectrum activity relevant to treatment resistant depression,” Neuropharmacology 66:202-214.
[cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/US2023/023586 dated Jul. 12, 2023, 13 pages.
[cited by applicant]
International Search Report mailed on Sep. 18, 2014, for PCT Application No. PCT/GB2014/052184, filed on Jul. 17, 2014, 3 pages.
[cited by applicant]
Johnson, Kari A. et al., “Allosteric modulation of metabotropic glutamate receptors in alcohol use disorder: Insights from preclinical investigations,” Adv Pharmacol., Mar. 2, 2020, vol. 88, pp. 193-232.
[cited by applicant]
Kavirajan, H. et al., “Efficacy and adverse effects of cholinesterase inhibitors and memantine in vascular dementia: a meta-analysis of randomised controlled trials,” Lancet Neural., Sep. 1, 2007, vol. 6, No. 9, pp. 782…
[cited by applicant]
Keck, Thomas M. et al., “Fenobam Sulfate Inhibits Cocaine-Taking and Cocaine-Seeking Behavior in Rats: Implications for Addiction Treatment in Humans,” Psychopharmacology (Berl.), Sep. 2013, vol. 229, No. 2, pp. 253-265.
[cited by applicant]
Keywood, C. et al. (2009). “A proof-of-concept study evaluating the effect of ADX10059, a metabotropic glutamate receptor-5 negative allosteric modulator, on acid exposure and symptoms in gastro-esophageal reflux diseas…
[cited by applicant]
King, A.O. et al. (1977). “Highly General Stereo-, Regio-, and Chemo-selective Synthesis of Terminal and Internal Conjugated Enynes by the Pd-catalysed Reaction of Alkenyl Reagents with Alkenyl Halides,” JC.S. Chem. Com…
[cited by applicant]
Kinney, G.G. et al. (2005). “A novel selective positive allosteric modulator of metabotropic glutamate receptor subtype 5 has in vivo activity and antipsychotic-like effects in rat behavioral models,” J. of Pharmacology…
[cited by applicant]
Liang, Y-C. et al. (2005). “Characterization of long-term potentiation of primary afferent transmission at trigeminal synapses of juvenile rats: essential role of subtype 5 metabotropic glutamate receptors,” Pain 114:41…
[cited by applicant]
Liu, M-G. et al. (2012). “Metabotropic glutamate receptor 5 contributes to inflammatory tongue pain via extracellular signal-regulated kinase signaling in the trigeminal spinal subnucleus caudalis and upper cervical spi…
[cited by applicant]
MacMaster, F.P. et al. (2003). “Proton spectroscopy in medication-free pediatric attention-deficit/hyperactivity disorder,” Biological Psychiatry 53:184-187.
[cited by applicant]
Melemis, SM, “Relapse Prevention and the Five Rules of Recovery,” Yale J Biol Med., Sep. 3, 2015, vol. 88, No. 3, pp. 325-332.
[cited by applicant]
Michalon, A. et al. (2012). “Chronic pharmacological mGlu5 inhibition corrects fragile X in adult mice,” Neuron 74:49-56.
[cited by applicant]
Mihov, Yoan et al., “Negative Allosteric Modulators of Metabotropic Glutamate Receptors Subtype 5 in Addiction: a Therapeutic Window,” International Journal of Neuropsychopharmacology, Jan. 8, 2016, vol. 19, No. 7, Arti…
[cited by applicant]
Mkhalid, I.A. et al. (2010). “C—H activation for the construction of C—B bonds,” Chem. Rev. 110:890-931.
[cited by applicant]
Monteith, T.S. et al. (2011). “Acute migraine therapy: new drugs and new approaches,” Current Treatment Options in Neurology 13:1-14.
[cited by applicant]
Nanau, RM et al., “Biomolecules and biomarkers used in diagnosis of alcohol drinking and in monitoring therapeutic interventions,” Biomolecules, 2015, vol. 5, No. 3, pp. 1339-1385.
[cited by applicant]
Olive, M. F. et al., “Metabotropic glutamate receptor ligands as potential therapeutics for addiction,” Curr Drug Abuse Rev., Jan. 2009, vol. 2, No. 1, pp. 83-989.
[cited by applicant]
Palmatier, M.I. et al. (2008). “Metabotropic glutamate 5 receptor (mGluR5) antagonists decrease nicotine seeking, but do not affect the reinforcement enhancing effects of nicotine,” Neuropsychopharmacology 33:2139-2147.
[cited by applicant]
Park, S-Y. et al. (2007). “Clinical significance of metabotropic glutamate receptor 5 expression in oral squamous cell carcinoma,” Oncology Reports 17:81-87.
[cited by applicant]
Porter, R.H. et al. (2005). “Fenobam a clinically validated nonbenzodiazepine anxiolytic is a potent, selective, and noncompetitive mGlu5 receptor antagonist with inverse agonist activity,” J. of Pharmacology and Experi…
[cited by applicant]
Rossi, D. et al. (2008). “Focal degeneration of astrocytes in amyotrophic lateral sclerosis,” Cell Death Differ. 15:1691-1700.
[cited by applicant]
Salling, M. C. et al., “Negative allosteric modulation of metabotropic glutamate receptor 5 attenuates alcohol self-administration in baboons,” Pharmacol Biochem Behav., Author Manuscript, Sep. 2021, vol. 208, Article N…
[cited by applicant]
Sanacora, G. et al. (2012). “Towards a glutamate hypothesis of depression an emerging frontier of neuropsychopharmacology for mood disorders,” Neuropharmacology 62:63-77.
[cited by applicant]
Schroeder et al., “The mGluR5 antagonist MPEP decreases operant ethanol self-administration during maintenance and after repeated alcohol deprivations in alcohol-preferring (P) rats,” Psychopharmacology, Apr. 2005, vol.…
[cited by applicant]
Sobell, L. C., et al., “Timeline follow-back: A technique for assessing self-reported alcohol consumption”, Measuring Alcohol Consumption: Psychosocial and Biochemical Methods (1992): 41-72.
[cited by applicant]
Sokol, D.K. et al. (2011). “Autism, Alzheimer disease, and fragile X: APP, FMRP, and mGluR5 are molecular links,” Neurology 76:1344-1352.
[cited by applicant]
STN Registry No. 959547-01-4, NIH Chemical Genomics Center database, entered STN: Dec. 26, 2007, 1 page.
[cited by applicant]
Tang, F.R. (2005). “Agonists and antagonists of metabotropic glutamate receptors: anticonvulsants and antiepileptogenic agents?” Current Neuropharmacology 3:299-307.
[cited by applicant]
Um, J.W. et al. (2013). “Metabotropic glutamate receptor 5 is a coreceptor for Alzheimer Aβ oligomer bound to cellular pi-ion protein,” Neuron 79:887-902.
[cited by applicant]
Vattakatuchery, J.J. et al., “Acetylcholinesterase inhibitors in cognitive impairment in Huntington's disease: A brief review,” World J. Psychiatry, Sep. 22, 2013, vol. 3, No. 3, pp. 62-64.
[cited by applicant]
Wang, Q. et al., “Block of long-term potentiation by naturally secreted and synthetic amyloid β-peptide in Hippocampal slices is mediated via activation of the kinases c-Jun N-terminal kinase, cyclin-dependent kinase 5,…
[cited by applicant]
Wang, R. et al., “Role of glutamate and NMDA receptors in Alzheimer's disease,” J. Alzheimer's Dis., 2017, vol. 57. No. 1041-1048.
[cited by applicant]
Yasuhara, A. et al., “Metabotropic glutamate receptors: potential drug targets for psychiatric disorders,” Open Medicinal Chemistry Journal, 2010, vol. 4, pp. 20-36.
[cited by applicant]
Nicoletti, F., “Metabotropic glutamate receptors: from the workbench to the bedside,” Neuropharmacology, Jun. 1, 2011, vol. 60, Nos. 7-8, pp. 1017-1041.
[cited by applicant]
American Psychiatric Association, “Substance Abuse Disorders,” In: Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition. Arlington, VA, American Psychiatric Association, 2013, pp. 481-590.
[cited by applicant]
Backstrom et al., “Ionotropic and metabotropic glutamate receptor antagonism attenuates cue-induced cocaine seeking,” Neuropsychopharmacology, Apr. 2006, vol. 31, No. 4, pp. 778-786.
[cited by applicant]
Baker et al., “Disulfiram effects on responses to intravenous cocaine administration,” Drug Alcohol Depend, Mar. 16, 2007, vol. 87, No. 2-3, pp. 202-209.
[cited by applicant]
Bentzley, “Comparison of Treatments for Cocaine Use Disorder Among Adults a Systematic Review and Meta-analysis,” JAMA Network Open, May 3, 2021, vol. 4, No. 5, e218049, 22 pages.
[cited by applicant]
Bird et al., “The mGlu5 receptor regulates extinction of cocaine-driven behaviours,” Drug Alcohol Depend, Apr. 2014, vol. 137, pp. 83-89.
[cited by applicant]
Brown-White, H., “Investigating metabotropic glutamate receptor 5 (mGlu5) as a novel therapeutic target in motor neuron disease (MND),” Thesis submitted for Sheffield Institute for Translational Neuroscience, Aug. 2018,…
[cited by applicant]
Campbell et al., “Increased alcohol-drinking induced by manipulations of mGlu5 phosphorylation within the bed nucleus of the stria terminalis,” Journal of Neuroscience, Apr. 3, 2019, vol. 39, No. 14, pp. 2745-2761.
[cited by applicant]
Ceccarini et al., “Recovery of Decreased Metabotropic Glutamate Receptor 5 Availability in Abstinent Alcohol-Dependent Patients,” J Nucl Med, Feb. 1, 2020, vol. 61, No. 2, pp. 256-262.
[cited by applicant]
Chiamulera et al., “Reinforcing and locomotor stimulant effects of cocaine are absent in mGluR5 null mutant mice.” Nature Neuroscience, Sep. 1, 2001, vol. 4, No. 9, pp. 873-874.
[cited by applicant]
ClinicalTrial.Gov. Study to Investigate Whether AFQ056 Reduces Cocaine Use in Patients Diagnosed With Cocaine Use Disorder (CUD) ClinicalTrial.Gov Identifier NCT03242928. 2012; Available from: https://clinicaltrials.gov…
[cited by applicant]
ClinicalTrials.gov, “A Study to Investigate the Interaction Between TMP-301 and Cocaine,” Tempero Bio, Inc. NCT06648668, last updated Feb. 21, 2025, 12 pages, at url: https://clinicaltrials.gov/study/NCT06648668?spons=T…
[cited by applicant]
ClinicalTrials.gov, “A Study to Investigate the Safety and Efficacy of TMP-301 Compared to Placebo in Adult Patients With Alcohol Use Disorder,” Tempero Bio, Inc. NCT06648655, last updated Feb. 21, 2025, 8 pages, at url…
[cited by applicant]
ClinicalTrials.gov, “Multiple Ascending Dose Study of TMP-301 in Healthy Subjects,” ClinicalTrials.gov ID No. NCT06025396, last updated Jan. 17, 2024, 8 pages.
[cited by applicant]
Cozzoli et al., “Nucleus Accumbens mGluR5-Associated Signaling Regulates Binge Alcohol Drinking Under Drinking-in-the-Dark Procedures,” Alcohol Clin Exp Res., Sep. 2012, vol. 36, No. 9, pp. 1623-1633.
[cited by applicant]
Evans et al., “Effect of flupenthixol on subjective and cardiovascular responses to intravenous cocaine in humans,” Drug Alcohol Depend., Nov. 1, 2001, vol. 64, No. 3, pp. 271-283.
[cited by applicant]
Haile et al., “Genetics of Dopamine and its Contributions to Cocaine Addiction,” Behav. Genet., Jan. 2007, vol. 37, pp. 119-145.
[cited by applicant]
Harris et al., “A phase 1 trial of pharmacologic interactions between transdermal selegiline and a 4-hour cocaine infusion,” BMC Clin Pharmacol., Dec. 2009, vol. 9, pp. 1-8.
[cited by applicant]
Hart et al., “Comparison of intravenous cocaethylene and cocaine in humans,” Psychopharmacology, Apr. 2000, vol. 149, No. 2, pp. 153-162.
[cited by applicant]
Hodge et al., “The mGluR5 antagonist MPEP selectively inhibits the onset and maintenance of ethanol self-administration in C57BL/6J mice,” Psychopharmacology, Jan. 2006, vol. 183, No. 4, pp. 429-438.
[cited by applicant]
Hoffman et al., “The novel mGluR5 negative allosteric modulator TMP-301 significantly reduces home-cage alcohol drinking and operant alcohol self-administration in rats,” UNC School of Medicine, Bowles Center for Alcoho…
[cited by applicant]
Hoffman et al.,“The novel mGluR5 negative allosteric modulator TMP-301 significantly reduces home-cage alcohol drinking and operant alcohol self-administration in rats,” in 45th Annual Speaker & Poster Abstracts of the …
[cited by applicant]
Holmes et al., “Altered metabotropic glutamate receptor 5 markers in PTSD: In vivo and postmortem evidence,” Proceedings of the National Academy of Sciences, Aug. 1, 2017, vol. 114, No. 31, pp. 8390-8395.
[cited by applicant]
Holmes et al., “Glutamatergic targets for new alcohol medications,” Psychopharmacology, Oct. 2013, vol. 229, No. 3, pp. 539-554.
[cited by applicant]
Johnson et al., “Effects of acute intravenous cocaine on cardiovascular function, human learning, and performance in cocaine addicts,” Psychiatry Res., Jan. 16, 1998, vol. 77, No. 1, pp. 35-42.
[cited by applicant]
Jones et al., “Subjective and physiological effects of intravenous nicotine and cocaine in cigarette smoking cocaine abusers,” JPET, Jan. 1999, vol. 288, No. 1, pp. 188-197.
[cited by applicant]
Kalivas et al., “The glutamate homeostasis hypothesis of addiction,” Nature Reviews Neuroscience, Aug. 2009, vol. 10, No. 8, pp. 561-572.
[cited by applicant]
Kampman, “The treatment of cocaine use disorder,” Sci. Adv., Oct. 16, 2019, vol. 5, No. 10, eaax1532, 8 pages.
[cited by applicant]
Kiluk et al., “Quality vs Quantity: Acquisition of Coping Skills Following Computerized Cognitive Behavioral Therapy for Substance Use Disorders,” Addicition, 2010, vol. 105, No. 12, pp. 2120-2127.
[cited by applicant]
Kumaresan et al., “Metabotropic glutamate receptor 5 (mGluR5) antagonists attenuate cocaine priming-and cue-induced reinstatement of cocaine seeking,” Behavioural Brain Research, Sep. 14, 2009, vol. 202, No. 2, pp. 238-…
[cited by applicant]
Leurquin-Sterk et al., “Cerebral dopaminergic and glutamatergic transmission relate to different subjective responses of acute alcohol intake: an in vivo multimodal imaging study,” Addiction Biology, May 2018, vol. 23, …
[cited by applicant]
Li et al., “Pu-erh tea protects the nervous system by inhibiting the expression of metabotropic glutamate receptor 5,” Molecular Neurobiology, Sep. 2017, vol. 54, pp. 5486-5499.
[cited by applicant]
Mahesarajah et al., “The global effects of alcohol consumption on Gross Domestic Product in high- and low-income countries: a systematic review and meta-analysis,” medRxiv, Apr. 28, 2022, 29 pages.
[cited by applicant]
Mallinckrodt et al., “Recent Developments in the Prevention and Treatment of Missing Data,” Therapeutic Innovation & Regulatory Science, Jan. 2014, vol. 48, No. 1, pp. 68-80.
[cited by applicant]
Mallinckrodt et al., “Recommendations for the Primary Analysis of Continuous Endpoints in Longitudinal Clinical Trials,” Drug information journal : DIJ / Drug Information Association, Jul. 2008, vol. 42, No. 4, pp. 303-…
[cited by applicant]
McKetin, “Recreational drug use and binge drinking: stimulant but not cannabis intoxication is associated with excessive alcohol consumption,” Drug and Alcohol Review, Jul. 2014, vol. 33, No. 4, pp. 436-445.
[cited by applicant]
Mello et al., “Effects of the mixed mu/kappa opioid nalbuphine on cocaine-induced changes in subjective and cardiovascular responses in men,” Neuropsychopharmacology, Mar. 2005, vol. 30, No. 3, pp. 618-632.
[cited by applicant]
Mezinskis et al., “Craving and withdrawal symptoms for various drugs of abuse,” Psychiatric Annals Oct. 1998, vol. 28, No. 10, pp. 577-583.
[cited by applicant]
Molenberghs et al., “Analysis of the Depression Trials,” in Missing Data in Clinical Studies, Apr. 4, 2007, pp. 67-74.
[cited by applicant]
Mora et al., “CYP450 and its implications in the clinical use of antipsychotic drugs,” Journal of Clinical & Experimental Pharmacology, May 2015, vol. 5, Issue 2, Article No. 1000176, 10 pages.
[cited by applicant]
Nelson et al., “Effect of rate of administration on subjective and physiological effects of intravenous cocaine in humans,” Drug Alcohol Depend., Mar. 15, 2006, vol. 82, No. 1, pp. 19-24.
[cited by applicant]
Niswender et al., “Metabotropic glutamate receptors: physiology, pharmacology, and disease,” Annu Rev Pharmacol Toxicol., Feb. 10, 2010, vol. 50, No. 1, pp. 295-322.
[cited by applicant]
Novartis, “Technical result summary for a randomized, subject- and Investigator-blinded, placebo-controlled, parallel-group study to investigate whether AFQ056 reduces cocaine use in patients diagnosed with Cocaine Use …
[cited by applicant]
Olive et al., “The mGluR5 Antagonist 6-Methyl-2-(phenylethynyl)pyridine Decreases Ethanol Consumption via a Protein Kinase C-Dependant Mechanism,” Molecular Pharmacology, Feb. 1, 2005, vol. 67, No. 2, pp. 349-355.
[cited by applicant]
Pasanen et al., “The role of CYP enzymes in cocaine-induced liver damage,” Arch Toxicol., Mar. 1995, vol. 69, No. 5, pp. 287-290.
[cited by applicant]
Robinson et al., “Reliability of the timeline followback for cocaine, cannabis, and cigarette use,” Psychol Addict Behav., Mar. 2014, vol. 28, No. 1, pp. 154-162.
[cited by applicant]
Romach et al., “Attenuation of the euphoric effects of cocaine by the dopamine D1/D5 antagonist ecopipam (SCH 39166),” Arch Gen Psychiatry, Dec. 1, 1999, vol. 56, No. 12, pp. 1101-1106.
[cited by applicant]
Rotheram-Fuller et al., “Subjective and cardiovascular effects of cocaine during treatment with amantadine and baclofen in combination,” Psychiatry Res., Aug. 30, 2007, vol. 152, Nos. 2-3, pp. 205-210.
[cited by applicant]
Schroeder et al., “Cue-induced reinstatement of alcohol-seeking behavior is associated with increased ERK1/2 phosphorylation in specific limbic brain regions: blockade by the mGluR5 antagonist MPEP,” Neuropharmacology, …
[cited by applicant]
Sobell et al., “The reliability of a timeline method for assessing normal drinker college students' recent drinking history: utility for alcohol research,” Addict Behav., Jan. 1, 1986, vol. 11, No. 2, pp. 149-161.
[cited by applicant]
Tempero Bio, “Advancing the Journey to Recovery,” Corporate Presentation, Jan. 18, 2023, 17 pages.
[cited by applicant]
Waldron, J., “Stalicla pledges $270M to take forward Novartis' failed former fragile X candidate,” Fierce Biotech, Jan. 9, 2023, 2 pages.
[cited by applicant]
Walsh et al., “Fluoxetine alters the effects of intravenous cocaine in humans,” J Clin Psychopharmacol., Dec. 1994, vol. 14, No. 6, pp. 396-407.
[cited by applicant]
Wang et al., “Role of glutamate and NMDA receptors in Alzheimer's disease,” J. Alzheimer's Dis., Apr. 19, 2017, vol. 57. No. 4, pp. 1041-1048.
[cited by applicant]
World Heath Organization (WHO), “WHO Global Status Report on alcohol and health and treatment of substance use disorders,” World Heath Organization, Jun. 2024, 334 pages.
[cited by applicant]
Zernig et al., “Giacomuzzi S, Riemer Y, Wakonigg G, Sturm K, Saria A. Intravenous drug injection habits: drug users' self-reports versus researchers' perception,” Pharmacology, Apr. 3, 2003, vol. 68, No. 1, pp. 49-56.
[cited by applicant]